Knopf Andreas, Bas Murat, Hofauer Benedikt, Mansour Naglaa, Stark Thomas
Technische Universität München, Hals-Nasen-Ohrenklinik und Poliklinik, München, Germany.
Head Neck. 2017 Jan;39(1):92-97. doi: 10.1002/hed.24540. Epub 2016 Jul 22.
There are still controversies about the therapeutic strategies and subsequent outcome in head and neck Merkel cell carcinoma.
Clinicopathological data of 23 Merkel cell carcinomas, 93 cutaneous head and neck squamous cell carcinomas (HNSCCs), 126 malignant melanomas, and 91 primary parotid gland carcinomas were comprehensively analyzed. Merkel cell carcinomas were cytokeratin 20 (CK20)/neuron-specific enolase (NSE)/chromogranin A (CgA)/synaptophysin (Syn)/thyroid transcription factor-1 (TTF-1)/MIB1 immunostained.
All Merkel cell carcinomas underwent wide local excision. Parotidectomy/neck dissection was performed in 40%/33% cutaneous Merkel cell carcinoma and 100%/100% in parotid gland Merkel cell carcinoma. Five-year recurrence-free interval (RFI)/overall survival (OS) was significantly higher in malignant melanoma (81/80%) than in cutaneous Merkel cell carcinoma/HNSCC. Interestingly, 5-year RFI/OS was significantly higher in Merkel cell carcinoma (61%/79%) than in HNSCC (33%/65%; p < .0001) despite comparable TNM classifications and treatment regimens. There were neither differences of RFI/OS between parotid gland Merkel cell carcinoma and parotid gland carcinomas, nor in the immunohistochemical profile.
Five-year RFI/OS was significantly better in cutaneous Merkel cell carcinoma when compared with TNM classification matched HNSCC. Five-year RFI/OS was comparable in parotid gland Merkel cell carcinoma and other primary parotid gland malignancies. © 2016 Wiley Periodicals, Inc. Head Neck 39: 92-97, 2017.
头颈部默克尔细胞癌的治疗策略及后续结果仍存在争议。
对23例默克尔细胞癌、93例皮肤头颈部鳞状细胞癌（HNSCC）、126例恶性黑色素瘤和91例原发性腮腺癌的临床病理数据进行综合分析。对默克尔细胞癌进行细胞角蛋白20（CK20）/神经元特异性烯醇化酶（NSE）/嗜铬粒蛋白A（CgA）/突触素（Syn）/甲状腺转录因子-1（TTF-1）/MIB1免疫染色。
所有默克尔细胞癌均行广泛局部切除。40%/33%的皮肤默克尔细胞癌行腮腺切除术/颈部淋巴结清扫术，腮腺默克尔细胞癌的这一比例为100%/100%。恶性黑色素瘤的5年无复发生存期（RFI）/总生存期（OS）显著高于皮肤默克尔细胞癌/HNSCC。有趣的是，尽管TNM分类和治疗方案相当，但默克尔细胞癌的5年RFI/OS（61%/79%）显著高于HNSCC（33%/65%；p <.0001）。腮腺默克尔细胞癌与腮腺癌之间的RFI/OS以及免疫组化特征均无差异。
与TNM分类匹配的HNSCC相比，皮肤默克尔细胞癌的5年RFI/OS显著更好。腮腺默克尔细胞癌与其他原发性腮腺恶性肿瘤的5年RFI/OS相当。©2016威利期刊公司。《头颈》39: 92 - 97，2017年。
